Market News

Partnership by Market key Players

The key market players are focusing on the various strategies such as partnership as well as acquisitions is expected to propel the market growth over the forecast period. For instance, in November 2021, Organon group of companies, a global health care company and Forendo Pharma, a developer of novel drugs intended for the treatment of urological and other endocrinological diseases, announced that the companies have entered into a definitive agreement, under which Organon will acquire Forendo, a clinical-stage drug development company focused on novel treatments in women’s health. Forendo is pioneering the science of intracrinology, addressing disease through a novel, tissue-specific approach. Its lead clinical compound is an investigational, potentially first-in-class oral 17β-hydroxysteroid dehydrogenase type 1 (HSD17B1) inhibitor in early clinical development for endometriosis, being evaluated for its potential effect on endometriotic lesions. Endometriosis is a common and chronic condition that affects up to 1 in 10 women of reproductive age, causes abdominal pain and is associated with infertility.

Global Human Reproductive Technologies Market- Cross Sectional Analysis:

Rising incidence of maternal mortality, increasing population, and increasing family planning led to the increase demand for the infertility drugs, and contraceptive drugs and devices and this is expected to boost demand for human reproductive technologies market in North America region. For instance in May 2021, according to the Guttmacher Institute, in 2020, 60% of U.S. women aged 15–49 were using a contraceptive method and of sexually experienced U.S. women aged 15–44 have used at least one contraceptive method.

Global Human Reproductive Technologies Market: Key Developments

In July 2022, Organon group of companies, a global women’s healthcare company, and Cirqle Biomedical, a biotech company developing a non-hormonal contraceptive technology for women based on the principles of mucus engineering, announced they have entered into a research collaboration and exclusive license agreement for a novel investigational non-hormonal, on-demand contraceptive candidate.

In June 2022, Inception Fertility LLC, a tech-enabled company with a steadfast focus on improving the patient experience through a growing ecosystem of integrated fertility brands, has expanded its ecosystem to include the launch of HavenCryo, a long-term reproductive tissue and cryopreservation storage solution that offers a unique experience for fertility providers and patients. HavenCryo offers the most advanced cryopreservation available, paired with state-of-the-art storage equipment and industry-leading security technologies, allowing patients to store their reproductive tissues for as long as they need.

On March 28, 2023, Cryoport, Inc., a global provider of innovative temperature-controlled supply chain solutions for the life sciences industry and in supply chain solutions for the reproductive medicine markets, announced a multi-year agreement with Inception Fertility LLC, the tech-enabled company with a steadfast focus on improving the patient experience through a growing ecosystem of integrated fertility brands. Through this three-year partnership, Prelude Fertility, Inc., which is operated by Inception Fertility LLC in North America and MyEggBank, most diverse networks of donor egg banks in North America will continue to utilize Cryoport, Inc., end-to-end supply chain solutions for egg and embryo shipments across their clinical networks to ensure significant risk mitigation for families using these services.

In August 2021, Virtus Health, a global Assisted Reproductive Services (ARS) provider, announced that it has entered into a share sale agreement to acquire Adora Fertility and three day hospitals from Australia-based healthcare company, Healius Limited, an Australia-based healthcare company for US$ 45 million.